PMID: 8943062Nov 26, 1996Paper

Efficient gene transfer by a human immunodeficiency virus type 1 (HIV-1)-derived vector utilizing a stable HIV packaging cell line

Proceedings of the National Academy of Sciences of the United States of America
P CorbeauF Wong-Staal

Abstract

By transfecting fibroblast cells with an HIV-1-MN molecular clone with a deletion of the major packaging sequence, we have developed a stable HIV-1 packaging cell line, psi 422, psi 422 cells form syncytia with CD4-positive cells, correctly express HIV-1 structural proteins, and produce a large amount of mature particles with normal reverse transcriptase activity. Yet these particles, in which RNA was not detected by reverse transcriptase-PCR, are not infectious. When stably transfected with an HIV-1-based retroviral vector, the psi 422 cell line produces virions capable of transducing CD4-positive cells with high efficiency (up to 10(5) cells per ml). The availability of this stable noninfectious HIV-1 packaging cell line capable of generating high-titer HIV-1 vectors represents a new step toward the use of an HIV-1 delivery system in gene therapy.

References

May 11, 1992·Journal of Virology·G L Buchschacher, A T Panganiban
Jun 1, 1992·Virology·T HayashiH Shibuta
Jan 1, 1987·AIDS Research and Human Retroviruses·L RatnerF Wong-Staal
Apr 1, 1981·Proceedings of the National Academy of Sciences of the United States of America·R C Mulligan, P Berg
Jun 21, 1994·Biochimica Et Biophysica Acta·K J SpringR H Don

❮ Previous
Next ❯

Citations

Aug 26, 1998·Critical Reviews in Oncology/hematology·G KaravanasM Piechaczyk
Jan 9, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Sophie BroussauBernard Massie
Jan 5, 1999·Haemophilia : the Official Journal of the World Federation of Hemophilia·S Connelly, M Kaleko
Feb 8, 2003·DNA and Cell Biology·Ricardo Quinonez, Richard E Sutton
Jun 19, 2013·Human Gene Therapy Methods·Anna StornaiuoloChiara Bovolenta
Feb 4, 1998·Human Gene Therapy·M J GoldmanJ M Wilson
Dec 1, 2001·Expert Opinion on Biological Therapy·S PandyaV Planelles
Dec 8, 2009·Medicinal Research Reviews·Ainhoa MuruaJosé Luis Pedraz
May 6, 1998·Virology·P Corbeau, F Wong-Staal
Apr 26, 2001·Molecular Therapy : the Journal of the American Society of Gene Therapy·S SparacioV Bosch
Sep 1, 2004·Molecular Therapy : the Journal of the American Society of Gene Therapy·Meera IyerSanjiv S Gambhir
Apr 8, 2003·Nature Biotechnology·Yasuhiro IkedaMary Collins
Feb 21, 2002·Cancer Investigation·Paul SchwarzenbergerVincent La Russa
Feb 12, 2008·Current Protocols in Molecular Biology·Ali Ramezani, Robert G Hawley
Dec 16, 1998·Journal of Virology·T KafriI M Verma
Apr 10, 1999·Journal of Virology·M Wu, A Mergia
Aug 19, 2000·Molecular Therapy : the Journal of the American Society of Gene Therapy·N KlagesD Trono
Jan 18, 2005·The Journal of Surgical Research·Lori D ConklinRichard E Sutton

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.